Treatment of triple negative breast cancer (TNBC): current options and future perspectives.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cancer Treatment Reviews

• Publication date

  2010-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0305-7372(10)70025-6PMID 21129616
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [PARP inhibitors for cancer therapy].

  2011cited by this paper
• Adjuvant therapy of triple negative breast cancer

  2010cited by this paper
• Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

  2010cited by this paper
• Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

  2009cited by this paper
• Triple-negative breast cancer: novel therapies and new directions.

  2009cited by this paper
• Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657).

  2009cited by this paper
• PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.

  2009cited by this paper
• SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).

  2009cited by this paper
• Triple-negative breast cancer--current status and future directions.

  2009cited by this paper
• BRCA1 gene expression signature predicts for anthracycline-chemosensitivity in triple-negative breast cancer.

  2009cited by this paper
• Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.

  2009cited by this paper
• Significantly higher expression of vascular endothelial growth factor (VEGF) and shorter survival after recurrences in premenopausal node negative patients with triple negative breast cancer

  2009cited by this paper
• Pharmacotherapy of triple-negative breast cancer

  2009cited by this paper
• Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF.

  2009cited by this paper
• A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy.

  2009cited by this paper
• Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer.

  2009cited by this paper
• Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial.

  2009cited by this paper
• Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

  2009cited by this paper
• First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors

  2008cited by this paper
• AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

  2008cited by this paper
• A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors

  2008cited by this paper
• Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

  2008cited by this paper
• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

  2008cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer

  2008cited by this paper
• HER2 and response to paclitaxel in node-positive breast cancer.

  2008cited by this paper
• A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

  2008cited by this paper
• The potential role and application of PARP inhibitors in cancer treatment.

  2008cited by this paper
• Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive

  2008cited by this paper
• Are BRCA1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple-negative breast cancers?

  2007cited by this paper
• The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

  2007cited by this paper
• Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience.

  2007cited by this paper
• HER2 and response to paclitaxel in node-positive breast cancer.

  2007cited by this paper
• First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers

  2007cited by this paper
• Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer

  2007cited by this paper
• Erlotinib-Induced Breast Cancer Regression

  2006cited by this paper
• Poly(ADP-ribose): novel functions for an old molecule

  2006cited by this paper
• Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA).

  2006cited by this paper
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  2005cited by this paper
• ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors

  2005cited by this paper
• PARP inhibitors for cancer therapy

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.

  2003cited by this paper
• DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis.

  2002cited by this paper
• A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer

  2002cited by this paper
• BRCA2 is required for homology-directed repair of chromosomal breaks.

  2001cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Genome maintenance mechanisms for preventing cancer

  2001cited by this paper
• Brca1 controls homology-directed DNA repair.

  1999cited by this paper
• Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme.

  1963cited by this paper

• Targeting the D93 cryptic collagen epitope alters integrin α2β1-dependent cellular migration and collagen remodeling in metastatic breast cancer

  2026cites this paper
• Machine learning and single-cell analysis uncover distinctive characteristics of CD300LG within the TNBC immune microenvironment: experimental validation

  2025cites this paper
• Exploring graph-based models for predicting active compounds against triple-negative breast cancer.

  2025cites this paper
• Engineering Complexity: Advances in 3D Breast Cancer Models for Precision Oncology

  2025cites this paper
• Berberine Sensitises Breast Cancer Cells to Radiation via the Attenuation of DNA Ligase III

  2025cites this paper
• Exploring the therapeutic potential of Thiosemicarbazones-ruthenium (II) complexes: In vitro evaluation

  2025cites this paper
• Crosslinked hydroxypropyl-β-cyclodextrin nanoparticles for improved efficacy of venetoclax against triple negative breast cancer.

  2025cites this paper
• Ratio of T-cell Subsets Predicts Prognosis in Triple-Negative Breast Cancer Patients

  2025cites this paper
• Structure-guided design and engineering of a biparatopic antibody targeting CCR2 in triple negative breast cancer.

  2025cites this paper
• Actin-Like Protein 6A as an Oncogene and Therapeutic Target in Cancer

  2025cites this paper
• Turning the Spotlight Away from PDT: Chemodynamic Dominance of 2-(2-Bromopyridin-4-yl)-1H-imidazo[4,5-f][1,10]phenanthroline Based Ru(II)/Ir(III)/Re(I) Complexes against MDA-MB-231.

  2025cites this paper
• Wild-type IDH2 is a therapeutic target for triple-negative breast cancer

  2024cites this paper
• Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models.

  2024cites this paper
• Identification of immune-related prognostic biomarkers in triple-negative breast cancer

  2024cites this paper
• MOLECULAR TARGETS AS POTENTIAL PI3Kα INHIBITORS AGAINST AGGRESSIVE METASTATIC DUCTAL AND LOBULAR CARCINOMA

  2024cites this paper
• A Microfluidic 3D‐Tumor‐Spheroid Model for the Evaluation of Targeted Therapies from Angiogenesis‐Related Cytokines at the Single Spheroid Level

  2024cites this paper
• GAPVD1 Promotes the Proliferation of Triple-Negative Breast Cancer Cells by Regulating the ERK/MAPK Signaling Pathway.

  2024cites this paper
• Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer.

  2023cites this paper
• KPT‐330 and Y219 exert a synergistic antitumor effect in triple‐negative breast cancer through inhibiting NF‐κB signaling

  2023cites this paper
• Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer

  2023cites this paper
• CXC Chemokine Receptor Type 4 Antagonistic Gold Nanorods Induce Specific Immune Responses and Long-Term Immune Memory to Combat Triple-Negative Breast Cancer.

  2023cites this paper
• Site-specific controlled-release nanoparticles for immune reprogramming via dual metabolic inhibition against triple-negative breast cancer.

  2023cites this paper
• Sulfated polysaccharides of Laetiporus sulphureus fruiting bodies exhibit anti-breast cancer activity through cell cycle arrest, apoptosis induction, and inhibiting cell migration.

  2023cites this paper
• MicroRNA‑606 inhibits the growth and metastasis of triple‑negative breast cancer by targeting Stanniocalcin 1

  2023cites this paper
• Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer

  2023cites this paper
• Identification of a seven-gene signature and establishment of a prognostic nomogram predicting overall survival of triple-negative breast cancer

  2023influential citation
• siRNA targeting ABCB1 potentiates the efficacy of chemotherapy in human triple-negative breast cancer cells

  2022cites this paper
• Network Analysis Identifies Potential Small-Molecule Drugs Sensitizing Triple-Negative Breast Cancer to Tamoxifen: Small-Molecule Drugs Re-sensitizing TNBC to Tamoxifen

  2022cites this paper
• circAR-E2E4-miR-665-STAT3 axis is a potential regulatory network in triple-negative breast cancer

  2022cites this paper
• Identification of immune cell function in breast cancer by integrating multiple single-cell data

  2022cites this paper
• Internal Wireless Electrical Stimulation from Piezoelectric Barium Titanate Nanoparticles as a New Strategy for the Treatment of Triple-Negative Breast Cancer.

  2022cites this paper
• Long non-coding RNA ANRIL promotes chemoresistance in triple-negative breast cancer via enhancing aerobic glycolysis.

  2022cites this paper
• Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis.

  2022cites this paper
• GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies

  2022cites this paper
• Effectiveness of the Sanyin Formula Plus Chemotherapy on Survival in Women With Triple-Negative Breast Cancer: A Randomized Controlled Trial

  2022cites this paper
• Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy—A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study

  2022cites this paper
• Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC.

  2022cites this paper
• ERα36-High Cancer-Associated Fibroblasts as an Unfavorable Factor in Triple-Negative Breast Cancer

  2022cites this paper
• Metabolic Intervention Nanoparticles for Triple‐Negative Breast Cancer Therapy via Overcoming FSP1‐Mediated Ferroptosis Resistance

  2022cites this paper
• Photothermal therapy-mediated autophagy in breast cancer treatment: Progress and trends.

  2022cites this paper
• Up-regulated circBACH2 contributes to cell proliferation, invasion, and migration of triple-negative breast cancer

  2021cites this paper
• lncRNA MIR503HG inhibits cell proliferation and promotes apoptosis in TNBC cells via the miR-224-5p/HOXA9 axis

  2021influential citation
• Long non-coding RNA SChLAP1 regulates the proliferation of triple negative breast cancer cells via the miR-524-5p/HMGA2 axis

  2021cites this paper
• Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer

  2021cites this paper
• Trailblazing perspectives on targeting breast cancer stem cells.

  2021cites this paper
• PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC

  2021cites this paper
• DIAPH1 facilitates paclitaxel-mediated cytotoxicity of ovarian cancer cells.

  2021cites this paper
• Predicting Breast Cancer Gene Expression Signature by Applying Deep Convolutional Neural Networks From Unannotated Pathological Images

  2021cites this paper
• Long Non-Coding RNA ANRIL Promotes Doxorubicin Resistance in Triple-Negative Breast Cancer via Suppressing Glycolysis Through the MicroRNA-125a/ENO Pathway

  2021cites this paper
• Gene expression trend changes in breast cancer populations over two decades: insights from The Cancer Genome Atlas database

  2021cites this paper
• Ruthenium and iron metallodrugs: new inorganic and organometallic complexes as prospective anticancer agents

  2021cites this paper
• CircRNA hsa_circ_0006220 acts as a tumor suppressor gene by regulating miR-197-5p/CDH19 in triple-negative breast cancer

  2021cites this paper
• Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade.

  2021cites this paper
• SphK2/S1P Promotes Metastasis of Triple-Negative Breast Cancer Through the PAK1/LIMK1/Cofilin1 Signaling Pathway

  2021cites this paper
• Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple‐negative breast cancer through FRA‐1 regulation

  2021cites this paper
• Photoimmunotherapy with cetuximab-conjugated gold nanorods reduces drug resistance in triple negative breast cancer spheroids with enhanced infiltration of tumor-associated macrophages.

  2020cites this paper
• ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer

  2020cites this paper
• CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer

  2020cites this paper
• circUSP42 Is Downregulated in Triple-Negative Breast Cancer and Associated With Poor Prognosis

  2020cites this paper
• High BTBD7 expression positive is correlated with SLUG-predicted poor prognosis in hormone receptor-negative breast cancer

  2020cites this paper
• Novel insights on use of doxorubicin to treat chemoresistant TNBC by Immunotherapy

  2020cites this paper
• Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer.

  2020cites this paper
• PMEPA1/TMEPAI isoforms function via its PY and Smad‐interaction motifs for tumorigenic activities of breast cancer cells

  2020cites this paper
• Study of the Purification of 177Lu-DOTAELA Complex

  2020cites this paper
• Synthesis of micellar-like terpolymer nanoparticles with reductively-cleavable cross-links and evaluation of efficacy in 2D and 3D models of triple negative breast cancer.

  2020cites this paper
• Immune-related gene data-based molecular subtyping related to the prognosis of breast cancer patients

  2020cites this paper
• Recent advances in metabolomics of triple negative breast cancer

  2020cites this paper
• Thiocolchicoside and Colchicine Induced Apoptosis in Breast Cancer (MCF-7) Cells Via Up-regulated Expression of p53 Tumor Suppressor Protein Gene: An In vitro and In silico Docking Approaches

  2020cites this paper
• Luteinizing Hormone-Releasing Hormone (LHRH) Conjugated Magnetite Nanoparticles as MRI Contrast Agents for Breast Cancer Imaging

  2020cites this paper
• Hypoxia Alters the Response to Anti-EGFR Therapy by Regulating EGFR Expression and Downstream Signaling in a DNA Methylation–Specific and HIF-Dependent Manner

  2020cites this paper
• S-nitrosylation of CYR61 protein reduces triple- negative breast cancer metastasis ability

  2020cites this paper
• Twist1 accelerates tumour vasculogenic mimicry by inhibiting Claudin15 expression in triple‐negative breast cancer

  2020cites this paper
• Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer

  2020cites this paper
• Target Analysis and Mechanism of Podophyllotoxin in the Treatment of Triple-Negative Breast Cancer

  2020cites this paper
• Drug-encapsulated blend of PLGA-PEG microspheres: in vitro and in vivo study of the effects of localized/targeted drug delivery on the treatment of triple-negative breast cancer

  2020cites this paper
• Six novel immunoglobulin genes as biomarkers for better prognosis in triple-negative breast cancer by gene co-expression network analysis

  2019cites this paper
• Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast Cancer

  2019cites this paper
• CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression.

  2019cites this paper
• Berberine attenuates XRCC1‐mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs

  2019cites this paper
• Electro-Acupuncture Promotes Accumulation of Paclitaxel by Altering Tumor Microvasculature and Microenvironment in Breast Cancer of Mice

  2019cites this paper
• Sphingosine-kinase-1 signaling promotes metastasis of triple-negative breast cancer.

  2019influential citation
• Breast Cancer Metabolism: In Vitro Uptake Studies with 18 F-FDG Advanced Molecular Imaging and Interventional Radiology

  2019cites this paper
• Unraveling the South African Breast Cancer Story: The Relationship of Patients, Delay to Diagnosis, and Tumor Biology With Stage at Presentation in an Urban Setting.

  2019cites this paper
• The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer

  2019cites this paper
• Classifying Breast Cancer Subtypes Using Multiple Kernel Learning Based on Omics Data

  2019cites this paper
• In vitro cytotoxicity and in vivo zebrafish toxicity evaluation of Ru(ii)/2-mercaptopyrimidine complexes.

  2019cites this paper
• Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells

  2018cites this paper
• Transcriptomic and epigenetic analysis of breast cancer stem cells.

  2018cites this paper
• Histone deacetylase inhibitors alter the expression of molecular markers in breast cancer cells via microRNAs.

  2018cites this paper
• Enhanced cellular uptake of LHRH-conjugated PEG-coated magnetite nanoparticles for specific targeting of triple negative breast cancer cells.

  2018cites this paper
• Therapeutic positioning of secretory acetylated APE1/Ref-1 requirement for suppression of tumor growth in triple-negative breast cancer in vivo

  2018cites this paper
• Nicotine reduces effectiveness of doxorubicin chemotherapy and promotes CD44+CD24− cancer stem cells in MCF-7 cell populations

  2018cites this paper
• circEPSTI 1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression

  2018cites this paper
• circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression

  2018cites this paper
• 1 Breast and Ovarian Cancer Treatment : Facing Forward Women ́ s Health Care

  2018cites this paper
• Glycoprotein nmb Is Exposed on the Surface of Dormant Breast Cancer Cells and Induces Stem Cell-like Properties.

  2018cites this paper
• S100P and Ezrin promote trans-endothelial migration of triple negative breast cancer cells

  2018cites this paper
• Boswellia frereana suppresses HGF-mediated breast cancer cell invasion and migration through inhibition of c-Met signalling

  2018cites this paper
• Identification of the Novel Role of CD24 as an Oncogenesis Regulator and Therapeutic Target for Triple-Negative Breast Cancer

  2018cites this paper
• Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer

  2018cites this paper